Point of Care Diagnostics Market to Grow at a CAGR of 6.5% During the Forecast Period; Increasing Occurrence of Chronic Conditions to Propel Market Expansion

The global point of care diagnostics market size was valued at USD 31.57 billion in 2024. The market is projected to grow from USD 32.87 billion in 2025 to USD 51.19 billion by 2032, exhibiting a CAGR of 6.5% during the forecast period.

Fortune Business Insights™ presents this information in its report titled, “Point of Care Diagnostics Market Size, Share & Industry Analysis, By Product (Blood Glucose Monitoring, Infectious Disease Testing, Cardiometabolic Disease Testing, Pregnancy & Fertility Testing, Hematology Testing, and Others), By Sample (Blood, Nasal and Oropharyngeal Swabs, Urine, and Others), By End-User (Hospital Bedside, Physician’s Office Lab, Urgent Care & Retail Clinics, and Home & Self testing), and Regional Forecast, 2025-2032”. 

Point of care testing (POCT) refers to the testing that is arranged near to the site of patient care. Factors including ability to offer rapid and accurate disease detection, extensively growing occurrence of chronic conditions and a minimal turn around duration drives the overall market growth. Moreover, the growing emphasis of players operating in the market on adopting/developing products with innovative technology and features with different testing kits such as urinalysis testing kits, infectious diseases testing kits, hematology testing kits and others promotes the increasing product adoption.

Launch of Advanced Products by First Response to Augment the Market Development

In October 2024, First Response stated the launch of its new multi-check pregnancy test kit. The new test is featured with EasyCup technology for improved ergonomics.

Increasing Implementation of Multiplex-POC Platform Drives the Market Growth

The growing adoption of multiplex testing platforms attributes to the point of care diagnostics market growth. This enables simultaneous identification and detection of different pathogens or biomarkers from a particular sample, thus reducing the testing duration and increasing the diagnostic accuracy. Moreover, the healthcare facilities with limited resources are implementing different advanced platforms to handle disease burdens properly. Researchers and market players are highly engaged in improving the capabilities of such diagnostics platforms, resulting in its growing adoption and thus driving the market growth. Multiplex diagnostics is also known for its economic benefits by decreasing sample processing and turnaround periods, thus reducing operational costs and resource needs.

Conversely, the challenges related with result consistency and dependability are hindering market growth.

Top Players Emphasize R&D to Strengthen Their Market Presence

The global market is semi-consolidated by a few arrays of manufacturers working across countries. Key players concentrate on acquisitions and R&D to strengthen their market offering across the globe.

Notable Industry Development:

• March 2025: PS Fertility stated launch of its new PS Detect for diagnosis of varicocele. The test plays a dynamic role in decision making for surgical treatment decisions.

List of the Companies Profiled in the Report:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Abbott (U.S.)
• EKF Diagnostics Holdings plc (U.K.)
• Cardinal Health, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• BD (U.S.)
• bioMérieux SA (France)
• QuidelOrtho Corporation (U.S.)
• Bio-Rad Laboratories Inc. (U.S.)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/press-release/point-of-care-diagnostics-market-9219

Further Report Findings

• North America held the highest Point of Care Diagnostics market share, attributed to the strong penetration of unconventional point of care diagnostics to identify various chronic and infectious diseases.
• Market growth in Europe is due to the growing focus of key players in the region on launching fast diagnostics tests for the time-efficient diagnosis of different infectious diseases.
• Market expansion in Asia Pacific is propelled by an increase in prevalence of infectious diseases and chronic illnesses across the region.
• In terms of product, the blood glucose monitoring segment led the market in 2024, due to rising occurrence of diabetes among the population and increasing focus of different market players on launching innovative products with advanced technology and products.

Table of Segmentation